The 503B GLP-1 Ban: What the FDA Exclusion Means for Compounded Semaglutide
The FDA is permanently closing the door on large-scale compounded GLP-1 drugs. The comment period is over. The final rule is coming. Here is what patients on compounded semaglutide and tirzepatide need to understand.
On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The public comment period, extended once by 30 days, closed on July 30, 2026. A final rule is expected in the coming months.
If finalized, this shuts the last major regulatory pathway for large-scale compounding of these GLP-1 weight-loss drugs. At peak in 2024, compounded versions accounted for roughly 30% of total U.S. GLP-1 supply. That chapter is ending.
This article explains what happened, why, and what it means for the millions of patients who have been using compounded versions of these medications. If you are here because your compounded semaglutide is about to disappear, the practical alternatives are in the section below.
What Happened, in Order
Why the FDA Is Doing This
The FDA’s reasoning, stated plainly in the proposed rule, is that there is no clinical need for 503B outsourcing facilities to compound semaglutide, tirzepatide, or liraglutide from bulk substances. The shortages that originally justified large-scale compounding have resolved. FDA-approved products are commercially available. And the proposed exclusion would prevent 503B facilities from resuming bulk compounding even if future shortages occur.
The underlying logic: the broad compounding exception was always statutory, tied to specific conditions (shortage plus bulks-list eligibility). Once those conditions stopped being met, the exception was supposed to end. The proposed rule makes that ending permanent and explicit.
FDA Commissioner Marty Makary framed it directly: when FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need. The agency looked at all three GLP-1s and found none.
The FDA has also cited safety concerns as context for the exclusion. Compounded GLP-1 products have been linked to adverse event reports involving dosing errors (particularly from multi-dose vials), counterfeit API, and quality control failures. The agency has reported 455 adverse events associated with compounded GLP-1 products, contributing to the determination that the clinical need does not justify the safety tradeoffs when brand-name alternatives exist.
What Remains: The Alternatives
If you have been using compounded semaglutide or tirzepatide and need to transition, these are the pathways that remain.
Ozempic and Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide), Victoza and Saxenda (liraglutide). These are the FDA-approved products with established safety and efficacy data. Cost is the primary barrier — list prices run $800–$1,300/month, though manufacturer savings programs and insurance coverage can reduce this significantly.
The first oral GLP-1 with no food, water, or timing restrictions. 12.4% weight loss at the highest dose in clinical trials. Available from ~$149/month self-pay through LillyDirect, ~$25/month with commercial insurance. Beat oral semaglutide head-to-head. A genuine new option for patients who want GLP-1 therapy without injections.
503A compounding pharmacies may still compound GLP-1s for individual patients where documented medical necessity exists — meaning the commercially available product genuinely cannot meet that patient’s specific needs. This is much narrower than the broad access of the shortage era. The prescription must reflect a genuine clinical determination, not just cost preference.
Peptides like MOTS-c (which received a PCAC recommendation for obesity) and AOD-9604 (fat metabolism) operate through different mechanisms. They are not GLP-1 receptor agonists and do not produce the same magnitude of weight loss. But they are part of the expanding 503A peptide landscape and may be appropriate for some patients’ goals.
How This Connects to the Peptide Expansion
The 503B GLP-1 exclusion and the 503A peptide expansion are moving in opposite directions at the same time, and they are reshaping the telehealth market together.
Many telehealth companies built their businesses on compounded semaglutide and tirzepatide during the shortage era. With that revenue stream closing, these companies are pivoting toward non-GLP-1 peptides — BPC-157, TB-500, GHK-Cu, CJC-1295, and the other substances that received favorable PCAC recommendations. The commercial infrastructure (provider networks, pharmacy relationships, patient acquisition) is being redirected toward the peptides whose access is expanding.
For patients, this means more options for accessing peptide therapy through established telehealth channels. For the peptide market, it means more competition, more providers, and potentially downward pressure on pricing as scale increases. See our prescribing guide for how to navigate the current provider landscape.
The 503B exclusion applies to semaglutide, tirzepatide, and liraglutide — FDA-approved drugs with commercial alternatives. The 503A expansion applies to peptides like BPC-157, TB-500, and Semax — substances with no FDA-approved version and no USP monograph. These are different regulatory mechanisms operating on different substance categories. The 503A vs 503B explainer covers the structural differences.
Frequently Asked Questions
Sources
FDA proposed rule: exclusion of semaglutide, tirzepatide, and liraglutide from the 503B Bulks List (docket 2026-08552, April 30, 2026). Comment period extension and close: June 26 and July 30, 2026. FDA press announcement citing no clinical need. Regulatory analysis from Orrick, Frier Levitt, Epstein Becker Green, and Pharmacy Times. Foundayo (orforglipron) approval: FDA, April 1, 2026; ATTAIN-1 and ACHIEVE-3 trial data. Adverse event figures cited from FDA enforcement communications. Shortage resolution dates from the FDA drug shortage database.